Who should receive HMG CoA reductase inhibitors?

Drugs

Volumn 62, Issue 12, 2002, Pages 1707-1715

  Teo, Koon K ^a   Burton, Jeffrey R ^b  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN;

ADULT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DIABETES MELLITUS; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MALE; MORTALITY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; TREATMENT INDICATION;

FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0036346660     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262120-00001     Document Type: Review

References (36)

1. Is the relationship between serum cholesterol and risk of premature death from coronary disease continuous and graded?
2. Cholesterol and coronary heart disease: Future directions
3. The Lipid Research Clinics coronary primary prevention trials results: I. Reduction in incidence of coronary heart disease
4. Lowering cholesterol concentrations and mortality: A quantitative review of primary prevention trials
5. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin survival study (4S)
6. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
7. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
8. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
9. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
10. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and lose-dose anticoagulation on obstructive changes in saphenous-vein coronary artery bypass grafts
11. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B
12. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: The Canadian coronary atherosclerosis intervention trial
13. Effect of simvastatin on coronary atheroma: The multicentre anti-atheroma study (MAAS)
14. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (lipoprotein and coronary atherosclerosis study [LCAS])
15. Long term effects of cholesterol lowering and angiotensin converting enzyme inhibition on coronary atherosclerosis: The simvastatin/enalapril coronary atherosclerosis trial
16. Consistent gains by subgroups in retarding progression of coronary atherosclerosis due to long term lipid lowering therapy in normocholesterolemic patients
17. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebo controlled trial
18. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: The prospective pravastatin pooling project
19. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: Findings from the Scandinavian simvastatin survival study (4S)
20. Effect of simvastatin on alchemic signs and symptoms in the Scandinavian simvastatin survival study (4S)
21. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease
22. Statin trials and goals of cholesterol-lowering therapy
23. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL Study: A randomised controlled trial
24. Effect of coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolemic patients
25. HMG-CoA reductase inhibitors in the prevention of stroke
26. Are statins anti-inflammatory? Issues in the design and conduct of the pravastatin inflammation C-Reactive Protein evaluation
27. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction
28. Hyperlipidemia and coronary disease: Correction of the increased thrombogenic potential with cholesterol reduction
29. Lipid lowering and plaque regression: New insights into prevention of plaque disruption and clinical events in coronary disease
30. Atherosclerosis: Potential targets for stabilization and regression
31. Lipid-lowering therapy in low-risk patients. Commentary
32. The care gap: Improving delivery of patient care: Evidence based cardiovascular medicine
33. Time trends in the use of cholesterol-lowering agents in older adults
34. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease
35. Rationale and design of the Cardiac Hospitalization Atherosclerosis Management Program at the University of California Los Angeles